Current situation and management of gastrointestinal tumor-related emergencies

doi:10.16139/j.1007-9610.2025.01.15

Abstract

Abstract:

Cancer is still the main cause of death in the world. With the promotion of early cancer screening and the development of diagnosis and treatment technology, the 5-year survival rate of cancer patients has gradually increased, and more attention has been paid to the whole-process management of cancer patients. However, the incidence of tumor-related emergencies remains high, including a wide range of emergencies caused by initial tumor presentation, surgical complications, progression of known diseases, recurrence of previous cancers, and adverse reactions to treatment, some of which are life-threatening. In this review, we reviewed the current situation and management experience of gastrointestinal tumor-related emergencies.

Key words: Tumor emergency, Gastrointestinal neoplasm, Emergency management, Emergency medicine

CLC Number:

SUN Qiang, ZHANG Xin, YAO Jun, WANG Weijun. Current situation and management of gastrointestinal tumor-related emergencies[J]. Journal of Surgery Concepts & Practice, 2025, 30(01): 79-83.

References 41

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2]	NARAYANSWAMI J, SMITH D A, ENZERRA M, et al. "-Omas" presenting as "-itis": acute inflammatory presentations of common gastrointestinal neoplasms[J]. Emerg Radiol, 2019, 26(4):433-448. doi: 10.1007/s10140-019-01678-z pmid: 30719599
[3]	龙平. 综合医院肿瘤急症的特点与救治[J]. 中华肿瘤防治杂志, 2020, 27(S01):181,183.
	LONG P. Characteristics and treatment of tumor emergency in general hospital[J]. Chin J Cancer Control, 2020, 27(S01):181,183.
[4]	ZHOU Y, ABEL G A, HAMILTON W, et al. Diagnosis of cancer as an emergency: a critical review of current evidence[J]. Nat Rev Clin Oncol, 2017, 14(1):45-56. doi: 10.1038/nrclinonc.2016.155 pmid: 27725680
[5]	ROSNER M H, DALKIN A C. Electrolyte disorders associated with cancer[J]. Adv Chronic Kidney Dis, 2014, 21(1):7-17.
[6]	HWANG K, JEON D H, JANG H N, et al. Inappropriate antidiuretic hormone syndrome presenting as ectopic antidiuretic hormone-secreting gastric adenocarcinoma: a case report[J]. J Med Case Rep, 2014,8:185.
[7]	GOULD ROTHBERG B E, QUEST T E, YEUNG S J, et al. A comprehensive review[J]. CA Cancer J Clin, 2022, 72(6):570-593.
[8]	LEGRAND S B. Modern management of malignant hypercalcemia[J]. Am J Hosp Palliat Care, 2011, 28(7):515-517. doi: 10.1177/1049909111414164 pmid: 21724679
[9]	KHAN A A, GURNANI P K, PEKSA G D, et al. Bisphosphonate versus bisphosphonate and calcitonin for the treatment of moderate to severe hypercalcemia of malignancy[J]. Ann Pharmacother, 2021, 55(3):277-285.
[10]	NAGY-MIGNOTTE H, SHESTAEVA O, VIGNOUD L, et al. Prognostic impact of paraneoplastic Cushing's syndrome in small-cell lung cancer[J]. J Thorac Oncol, 2014, 9(4):497-505.
[11]	ORONSKY B, MA P C, MORGENSZTERN D, et al. Nothing but NET: a review of neuroendocrine tumors and carcinomas[J]. Neoplasia, 2017, 19(12):991-1002. doi: S1476-5586(17)30347-0 pmid: 29091800
[12]	COHEN A T, KATHOLING A, RIETBROCK S, et al. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study[J]. Thromb Haemost, 2017, 117(1):57-65.
[13]	OBITSU T, TANAKA N, OYAMA A, et al. Efficacy and safety of low-molecular-weight heparin on prevention of venous thromboembolism after laparoscopic operation for gastrointestinal malignancy in Japanese patients: a multicenter, open-label, prospective, randomized controlled trial[J]. J Am Coll Surg, 2020, 231(5):501-509.
[14]	STEVENS S M, WOLLER S C, BAUMANN KREUZIGER L, et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report[J]. Chest, 2021, 160(6):2247-2259.
[15]	HERMIE L, DHONDT E, VANLANGENHOVE P, et al. Empiric cone-beam CT-guided embolization in acute lower gastrointestinal bleeding[J]. Eur Radiol, 2021, 31(4):2161-2172.
[16]	TRONCONE E, FUGAZZA A, CAPPELLO A, et al. Malignant gastric outlet obstruction: which is the best therapeutic option?[J]. World J Gastroenterol, 2020, 26(16):1847-1860.
[17]	CHEN X J, CHEN G M, WEI Y C, et al. Palliative gastrectomy versus gastrojejunostomy for advanced gastric cancer with outlet obstruction: a propensity score matching analysis[J]. BMC Cancer, 2021, 21(1):188.
[18]	KAVANAGH D O, NOLAN B, JUDGE C, et al. A comparative study of short- and medium-term outcomes comparing emergent surgery and stenting as a bridge to surgery in patients with acute malignant colonic obstruction[J]. Dis Colon Rectum, 2013, 56(4):433-440. doi: 10.1097/DCR.0b013e3182760506 pmid: 23478610
[19]	NAMBA Y, HIRATA Y, MUKAI S, et al. Clinical indicators for the incidence of postoperative ileus after elective surgery for colorectal cancer[J]. BMC Surg, 2021, 21(1):80. doi: 10.1186/s12893-021-01093-7 pmid: 33573636
[20]	孙家琛, 陈俊榕, 刘亚男, 等. 肠梗阻导管联合生长抑素治疗老年胃肠道肿瘤术后早期炎性肠梗阻的临床疗效[J]. 中山大学学报:医学科学版, 2020, 41(5):741-746.
	SUN J C, CHEN J R, LIU Y N, et al. Effects of transnasal ileus tube combined with somatostatin on early postoperative inflammatory small bowel obstruction in elderly patients with gastrointestinal tumor[J]. J SUN YAT-SEN Univ(Med Sci), 2020, 41(5):741-746.
[21]	TAN K K, HONG C C, ZHANG J R, et al. Predictors of outcome following surgery in colonic perforation: an institution's experience over 6 years[J]. J Gastrointest Surg, 2011, 15(2):277-284.
[22]	DI CARLO S, FRANCESCHILLI M, ROSSI P, et al. Perforated gastric cancer: a critical appraisal[J]. Discov Oncol, 2021, 12(1):15. doi: 10.1007/s12672-021-00410-z pmid: 35201463
[23]	ISHIYAMA Y, MANABU AMIKI M O, ITO S. Anastomotic leakage following colorectal cancer surgery: comparison between conservative and surgical treatment[J]. Asian J Surg, 2021, 44(2):485-487. doi: 10.1016/j.asjsur.2020.11.006 pmid: 33229124
[24]	BIONDO S, GÁLVEZ A, RAMÍREZ E, et al. Emergency surgery for obstructing and perforated colon cancer: patterns of recurrence and prognostic factors[J]. Tech Coloproctol, 2019, 23(12):1141-1161. doi: 10.1007/s10151-019-02110-x pmid: 31728784
[25]	LINGAMANENI P, DESAI P, VENNIKANDAM M M, et al. Tumor lysis syndrome in a patient with gastric adenocarcinoma[J]. J Investig Med High Impact Case Rep, 2020,8:2324709620933427.
[26]	KOIZUMI W, NAKAYAMA N, TANABE S, et al. A multicenter phase Ⅱ study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)[J]. Cancer Chemother Pharmacol, 2012, 69(2):407-413.
[27]	ECKSTROM J, BARTELS T, ABRAHAM I, et al. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI[J]. Support Care Cancer, 2019, 27(3):873-878.
[28]	MILLER K D, NOGUEIRA L, MARIOTTO A B, et al. Cancer treatment and survivorship statistics,2019[J]. CA Cancer J Clin, 2019, 69(5):363-385.
[29]	WANG H, WANG L, JIANG Y L, et al. Long-term outcomes and prognostic analysis of computed tomography-guided radioactive ¹²⁵I seed implantation for locally recurrent rectal cancer after external beam radiotherapy or surgery[J]. Front Oncol, 2021,10:540096.
[30]	ANDREYEV H J, DAVIDSON S E, GILLESPIE C, et al. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer[J]. Gut, 2012, 61(2):179-192. doi: 10.1136/gutjnl-2011-300563 pmid: 22057051
[31]	刘越, 盛晶, 赵得堡, 等. 5-氟尿嘧啶/亚叶酸钙+奥沙利铂+伊立替康方案在老年晚期胃癌姑息治疗中的临床疗效[J]. 癌症进展, 2020, 18(24):2551-2554.
	LIU Y, SHENG J, ZHAO D B, et al. Clinical efficacy of 5-fluorouracil/calcium folin + oxaliplatin + irinotecan in palliative treatment of advanced gastric cancer in elderly patients[J]. Cancer Adv, 2020, 18(24):2551-2554.
[32]	ZHONG L, LI Y S, XIONG L, et al. Small molecules in targeted cancer therapy: advances,challenges,and future perspectives[J]. Signal Transduct Target Ther, 2021, 6(1):201.
[33]	ZHANG J, LUO D, LI F, et al. Ginsenoside Rg3 alle-viates antithyroid cancer drug vandetanib-induced QT interval prolongation[J]. Oxid Med Cell Longev, 2021,2021:3520034.
[34]	NIE C, LV H, CHEN B, et al. High DCR and better survival in patients with advanced or metastatic gastric cancer receiving anti-angiogenic TKI plus chemotherapy: a real-world study[J]. Technol Cancer Res Treat, 2023,22:15330338221150561.
[35]	AGIRGOL S, ÇAYTEMEL C, PILANCI K N. Dermatological side effects of targeted antineoplastic therapies: a prospective study[J]. Cutan Ocul Toxicol, 2020, 39(4):380-384. doi: 10.1080/15569527.2020.1833028 pmid: 33028137
[36]	JIANG L Y, PING L, YAN H, et al. Cardiovascular toxi-city induced by anti-VEGF/VEGFR agents: a special focus on definitions,diagnoses,mechanisms and management[J]. Expert Opin Drug Metab Toxicol, 2020, 16(9):823-835.
[37]	DING F, LIU B, WANG Y. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: a meta-analysis of 57 randomized controlled trials involving 24,956 patients[J]. J Am Acad Dermatol, 2020, 83(3):788-796. doi: S0190-9622(19)30607-3 pmid: 30991119
[38]	HAANEN J B A G, CARBONNEL F, ROBERT C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl 4):iv119-iv142.
[39]	MOSLEHI J J, SALEM J E, SOSMAN J A, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis[J]. Lancet, 2018, 391(10124):933. doi: S0140-6736(18)30533-6 pmid: 29536852
[40]	KOOSHKAKI O, DERAKHSHANI A, HOSSEINKHANI N, et al. Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials[J]. Int J Mol Sci, 2020, 21(12):4427.
[41]	HIGASHI T, MIYAMOTO H, YOSHIDA R, et al. Sjögren's syndrome as an immune-related adverse event of nivolumab treatment for gastric cancer[J]. Intern Med, 2020, 59(20):2499-2504.